- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Earlier Antipseudomonal De-escalation Is a Possibility in AML, Neutropenia
Patients with acute myeloid leukemia (AML) and febrile neutropenia that are de-escalated on day 5 if they were afebrile, hemodynamically stable, and without evidence of infection, had similar clinical outcomes and a decreased incidence of Clostridium difficile infections compared with patients without these early on re-evaluations for de-escalation.
Patients with acute myeloid leukemia (AML) and febrile neutropenia (FN) that are de-escalated on day 5 if they were afebrile, hemodynamically stable, and without evidence of infection, had similar clinical outcomes and a decreased incidence of Clostridium difficile (C difficile) infections compared with patients without these early on re-evaluations for de-escalation.
Patients with AML and FN need to be treated with dedicated care due to their immunosuppressed state. Both the Infectious Disease Society of America and National Comprehensive Cancer Network guidelines recommend continuing intravenous antipseudomonal therapy (IVPSA) until neutrophil recovery, defined as an absolute neutrophil count (ANC) > 500 cells/mm3. However, this standard of practice is being re-evaluated because of the increasing rates of multidrug­-resistant organisms and C difficile infection. To determine if the benefits of longer IVPSA therapy outweigh the risks, Alegria et al conducted an experimental study on whether IVPSA de-escalation affected patient outcomes.
Patients with AML were compared in 2 groups, the intervention and historical group. The historical group were patients who were enrolled before implementation of the guideline. In contrast, the intervention group were patients who were evaluated for antibiotic de-escalation on day 5 if they were afebrile, hemodynamically stable, and without evidence of infection, irrespective of their ANC.
What are the discharge guidelines for pediatric patients with febrile neutropenia?
Ninety-three patients with AML were included in this study (40 patients in the historical group, 53 patients in the intervention group). Between the 2 groups, clinical outcomes were very similar, except for the lower rates of C difficile infection and the shorter duration of IVPSA for the intervention group. Bacterial infection rates after antibiotic de-escalation were comparable, with 18 patients (45%) in the historical group and 18 patients (34%) in the intervention group (P = .292).
Similarly, the hospital length of stay (LOS) was not significantly different between the 2 groups (historical group, 25 days and intervention group, 27 days; P = .757). The incidence of C difficile infection, however, was significantly less in the intervention group (n = 3, 5.7%) than the historical group (n = 11, 27.5%; P = .007). Also, the duration of IVPSA was significantly less for the intervention group (14 days) compared with the historical group (25 days; P < .001).
The inappropriate use of antibiotics has resulted in an increase in C difficile infection and multidrug resistant organisms, leading to higher mortality for most of these immunosuppressed populations. By implementing a guideline to re-evaluate the need of IVPSA earlier on, patients can expect a decreased incidence of C difficile infection and a shorter duration of IVPSA therapy, while still effectively treating the infection.
Reference
Alegria W, Marini BL, Perissinotti AJ, Bixby D, Gregg K, Nagel J. Febrile neutropenia antibiotic de-escalation study in acute myeloid leukemia patients with prolonged neutropenia. In: Antimicrobial Stewardship: Special Populations; October 4, 2018; San Francisco, CA. Abstract 253. https://idsa.confex.com/idsa/2018/webprogram/Paper71717.html.
The Long-term Social Value of Granulocyte Colony-Stimulating Factors
October 4th 2019Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Read More
Patients with hematologic malignancy who are undergoing chemotherapy or a conditioning regimen for hematopoietic stem cell transplant (HSCT) are at high risk of infection because of the severity and duration of neutropenia. Fever with neutropenia is a common presentation that suggests an infection leading to empiric antibacterial therapy. To prevent infection and thus the neutropenic fever, antibacterial prophylaxis, especially with fluoroquinolones, emerged as a common practice based on results of 2 randomized controlled trials published in 2005 that showed reduced incidence of fever and bacteremia despite lack of a mortality benefit.
Read More
Neutropenia Etiology Influences Resulting Hematologic Consequences
March 2nd 2019Hematological consequences of severe chronic neutropenia vary based on the underlying etiology of the condition, according to a study abstract presented at the 60th American Society of Hematology Annual Meeting & Exposition.
Read More
Home Monitoring Device for Blood Cell, Neutrophil Counts Shows Positive Initial Results
February 22nd 2019Initial results of a study have found that white blood cell counts and absolute neutrophil counts, which are well-established predictors of risk of infections or febrile neutropenia, can be accurately measured with a finger stick drop of blood and point-of-care hematology results.
Read More
